Regarding CEDIA, which statement is correct?

CEDIA, which stands for Cloned Enzyme Donor Immunoassay, is a method used in clinical laboratories to measure drug levels in various samples. It relies on the principle of enzyme amplification and uses fragments of β-galactosidase as the key components.

The statement that the enzyme donor and acceptor molecules are fragments of β-galactosidase accurately reflects the mechanism of CEDIA. In this technique, an antibody binds to the target analyte (such as a drug), and this binding affects the interaction between the two enzyme fragments. When the drug is present, it competes with the enzyme fragments for binding, allowing for a measurable enzymatic reaction that produces a signal.

This process is vital because the use of β-galactosidase fragments allows for sensitive detection following the binding event. The binding causes a reconstitution of the enzyme activity, which can then be measured through fluorescence or another method of detection.

In contrast, other statements contain inaccuracies regarding the core principles of CEDIA. For instance, the enzyme glucose-6-phosphate dehydrogenase is not used in this assay; instead, the focus is on β-galactosidase. Similarly, while it is true that drug concentration